𝔖 Bobbio Scriptorium

✦ LIBER ✦

Secukinumab efficacy in subjects with moderate to severe plaque psoriasis: Pooled subgroup analyses by patient age of 4 phase 3 clinical studies

Book ID: 122214737
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 49 KB
Volume: 70
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2014.01.771

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Secukinumab safety in subjects with mode

Secukinumab safety in subjects with moderate to severe plaque psoriasis: A pooled analysis of neutropenia from 10 clinical studies

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Secukinumab efficacy in subjects with mo

Secukinumab efficacy in subjects with moderate to severe plaque psoriasis: A pooled analysis of patient-reported symptoms (pruritus, pain, and scaling) in 2 phase 3 clinical studies (ERASURE and FIXTURE)

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Secukinumab safety and tolerability in s

Secukinumab safety and tolerability in subjects with moderate to severe plaque psoriasis: A pooled subgroup analysis of 10 clinical studies evaluating exacerbation of Crohn’s disease

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Secukinumab efficacy and safety in subje

Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: Results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE)

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Efficacy and safety of ustekinumab in Ja

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

✍ Atsuyuki IGARASHI; Takeshi KATO; Mai KATO; Michael SONG; Hidemi NAKAGAWA; THE JA 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 462 KB

Long-term safety experience of ustekinum

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

✍ Mark Lebwohl; Craig Leonardi; Christopher E.M. Griffiths; Jörg C. Prinz; Philipp 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 243 KB